Physician profile
James Collins Corder
NPI 1184698987
$3,264.12
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,361 · 2020: $779 · 2021: $45.54 · 2022: $32.21 · 2023: $31.82 · 2024: $15.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $47.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $47.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $457.98 | 2019-2020 | |
| Novo Nordisk INC | $401.70 | 2019-2020 | |
| Allergan, INC. | $381.32 | 2019-2020 | |
| Pfizer INC. | $360.24 | 2019-2020 | |
| Lilly USA, LLC | $215.22 | 2019-2020 | |
| Amarin Pharma, INC. | $164.84 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.45 | 2019-2020 | |
| Glaxosmithkline, LLC. | $136.31 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $123.35 | 2019-2020 | |
| Abbott Laboratories | $99.54 | 2020-2021 | |
| Abbvie INC. | $95.72 | 2021-2024 | Ubrelvy |
| Kowa Pharmaceuticals America, INC. | $88.73 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.48 | 2019 | |
| Amgen INC. | $72.27 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $67.88 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $61.87 | 2019-2020 | |
| Antares Pharma, INC. | $55.59 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $51.42 | 2019 | |
| Sunovion Pharmaceuticals INC. | $44.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.02 | 2019 | |
| Merck Sharp & Dohme LLC | $30.52 | 2019-2020 | |
| Sanofi Pasteur INC. | $27.52 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $21.06 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.63 | 2019 | |
| Adlon Therapeutics L.P. | $13.69 | 2019 | |
| Insulet Corporation | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Corder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.